News | June 04, 2022
RH Capital announces investments to improve women’s health
RH Capital, a leading women's health venture capital fund, announced three new investments to improve health outcomes for women in the US.
RH Capital, a leading women's health venture capital fund, announced three new investments to improve health outcomes for women in the US.
Taiyin Yang, PhD, Executive Vice President, Pharmaceutical Development and Manufacturing to Retire After 29 Years at Gilead
120+ members of multi-disciplinary medical team are trained to provide seamless, outcome driven trauma and emergency care
Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma
The two-year agreement will grant Lonza access to IBF's prominent network and allow IBF to benefit from Lonza's manufacturing expertise and knowledge in its due diligence review of potential targets
Subscribe To Our Newsletter & Stay Updated
